The initial public offering (IPO) comprises a new allocation of equity shares valued at Rs 350 crore, as well as a sale of up to 90 lakh equity shares by the promoters, namely Hardeep Singh and Surmeet Kaur.
The three-day initial public offering (IPO) will conclude on June 8. The bidding for anchor investors will open on June 5, according to the red herring prospectus (RHP).
In the year 2022, approximately 109 SME firms went public, collectively raising around Rs 1,875 crore through IPOs. By comparison, in 2021, 59 SME firms were listed, raising a total of Rs 746 crore.
Nexus Select Trust is the fourth listed REIT after Embassy Office Parks, Mindspace Business Parks, and Brookfield India Real Estate Trust.
Nexus Select Trust, India's first retail assets focused REIT sponsored by global investment giant Blackstone, has raised Rs 3,200 crore via public issue.
Many believe that the grey market demand hints at a decent listing of around 4-5 percent on the issue price of Rs 100. After listing, the counter may get higher volume demand due to the lower allotment ratio in the entire IPO investor category, said an analyst
Blackstone-backed Nexus Select Trust IPO units are traded with 3-5 percent premium in the grey market over the expected final issue price of Rs 100 per unit, analysts on anonymity said.
The IPO comprises a fresh issue of Rs 615 crore and an offer for sale of up to 4.45 million shares by its existing shareholders and promoters.
Nexus Select Trust REIT IPO: Most brokerage houses have a 'subscribe rating', as they cite attractive valuations, best-in-class assets, and no listed real estate investment trusts in the retail sector in India
Nexus Select Trust REIT plans to raise Rs 3,200 crore via public issue which comprises a fresh issuance of units worth Rs 1,400 crore and an offer for sale of Rs 1,800 crore by selling shareholders.
JSW Infrastructure Ltd has filed a draft red herring prospectus with Securities Exchange Board of India to raise around Rs 2800 crore via initial public offerings. The entire IPO will be a pure fresh issue.
The Rs 3,200 crore-share sale received bids for 5,00,49,000 units against 17,60,00,100 units on offer.
Given its healthy financial track record, domestic focus and extensive network, Mankind is likely to continue doing well, Hemang Jani of Motilal Oswal believes.
Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.
Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company's revenue from operations in FY22
The Rs 4,326-crore IPO, which was subscribed 15.3 times, was one of the biggest by a domestic drug maker since Gland Pharma came up with a Rs 6,480-crore issue in 2020 and the biggest of 2023, so far
Nexus Select Trust plans to raise Rs 3,200 crore via IPO which comprises a fresh issuance of units worth Rs 1,400 crore, and an offer for sale of units worth Rs 1,800 crore
The rising grey market premium in the last few days, especially after improved market conditions, also indicates a strong listing
Nexus Select Trust proposes to utilize part of net proceeds towards the acquisition of a 30 percent stake in Nexus Indore Central (NMMCPL) from Olive Commercial Company Ltd.
ideaForge Technology filed its draft red herring prospectus with Sebi in February this year.
The public issue comprises a fresh issuance of shares worth Rs 625 crore, and an offer for sale of 1.7 crore equity shares by promoter and investors.
Nexus Select REIT will open for subscription on 9 May and close on 11 May. Anchor investors subscription will open on 8 May and finalisation of the basis of allotment will be on May 16. Initiation of refunds will be on May 17 and the stock will list on exchanges on 19 May.
Investors in the Mankind Pharma IPO can check their share allotment status on May 3.
The firm now plans to raise around Rs 750 crore via fresh issue from Rs 2000 crore earlier. The firm also cut its offer for sale to 20 million shares from 59 million shares earlier planned.
Mankind Pharma IPO final day: Qualified institutional buyers investors have bid 5.97 times their allotted quota, while the part set aside for high networth individuals has been subscribed 1.63 times